Immutep Wins FDA Orphan Drug Nod for Sarcoma Treatment Eftilagimod Alfa
Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.
MRKIMMPFDA approvalorphan drug designation